Discovery, Validation and Mechanistic Study of XPO1 Inhibition in the Treatment of Triple-Negative Breast Cancer is a research paper published in Cancers (2024). On theSindex it has a DataRank of 0.165. It has been cited 2 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH/NCI
Grant: R01CA204856
NIH/NCI
Grant: R01CA229618
NCI NIH HHS
Grant: T32 CA009138
National Institutes of Health
Grant: 5R01CA204856-05
Drug repurposing in breast cancer
National Institutes of Health
Grant: 5R01CA229618-05
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy
Fields of Study
Keywords